Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.08
(3.31%)
EUR 0.08
(3.31%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 20.46 Million EUR | -1.67% |
| 2022 | 20.81 Million EUR | 3.45% |
| 2021 | 20.12 Million EUR | 15.17% |
| 2020 | 17.47 Million EUR | -14.5% |
| 2019 | 20.43 Million EUR | 14.48% |
| 2018 | 17.84 Million EUR | -36.71% |
| 2017 | 28.19 Million EUR | -9.07% |
| 2016 | 31.01 Million EUR | 17.3% |
| 2015 | 26.43 Million EUR | -11.96% |
| 2014 | 30.02 Million EUR | 191.37% |
| 2013 | 10.3 Million EUR | -0.7% |
| 2012 | 10.37 Million EUR | -7.17% |
| 2011 | 11.17 Million EUR | 49.41% |
| 2010 | 7.48 Million EUR | -12.74% |
| 2009 | 8.57 Million EUR | -43.4% |
| 2008 | 15.14 Million EUR | -11.14% |
| 2007 | 17.04 Million EUR | 356.25% |
| 2006 | 3.73 Million EUR | 1.51% |
| 2005 | 3.68 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 25.31 Million EUR | 23.7% |
| 2024 Q2 | 25.31 Million EUR | 0.0% |
| 2023 Q4 | 20.46 Million EUR | -0.0% |
| 2023 Q3 | 20.46 Million EUR | -1.8% |
| 2023 FY | 20.46 Million EUR | -1.67% |
| 2023 Q2 | 20.84 Million EUR | 0.0% |
| 2023 Q1 | 20.84 Million EUR | 0.13% |
| 2022 Q1 | 26.8 Million EUR | 33.22% |
| 2022 FY | 20.81 Million EUR | 3.45% |
| 2022 Q4 | 20.81 Million EUR | 0.0% |
| 2022 Q3 | 20.81 Million EUR | -22.35% |
| 2022 Q2 | 26.8 Million EUR | 0.0% |
| 2021 FY | 20.12 Million EUR | 15.17% |
| 2021 Q1 | 22.23 Million EUR | 27.26% |
| 2021 Q3 | 20.12 Million EUR | -9.5% |
| 2021 Q4 | 20.12 Million EUR | 0.0% |
| 2021 Q2 | 22.23 Million EUR | 0.0% |
| 2020 Q3 | 17.47 Million EUR | -9.38% |
| 2020 Q2 | 19.27 Million EUR | 0.0% |
| 2020 Q4 | 17.47 Million EUR | 0.0% |
| 2020 FY | 17.47 Million EUR | -14.5% |
| 2020 Q1 | 19.27 Million EUR | -5.65% |
| 2019 Q1 | 19.94 Million EUR | 11.72% |
| 2019 FY | 20.43 Million EUR | 14.48% |
| 2019 Q4 | 20.43 Million EUR | 0.0% |
| 2019 Q3 | 20.43 Million EUR | 2.47% |
| 2019 Q2 | 19.93 Million EUR | -0.01% |
| 2018 Q1 | 6.07 Million EUR | -78.46% |
| 2018 Q2 | 16.05 Million EUR | 164.25% |
| 2018 Q3 | 17.84 Million EUR | 11.18% |
| 2018 Q4 | 17.84 Million EUR | 0.0% |
| 2018 FY | 17.84 Million EUR | -36.71% |
| 2017 Q1 | 10.97 Million EUR | -64.6% |
| 2017 FY | 28.19 Million EUR | -9.07% |
| 2017 Q4 | 28.19 Million EUR | 49.66% |
| 2017 Q3 | 18.84 Million EUR | -34.31% |
| 2017 Q2 | 28.68 Million EUR | 161.31% |
| 2016 FY | 31.01 Million EUR | 17.3% |
| 2016 Q3 | 12.41 Million EUR | -51.43% |
| 2016 Q2 | 25.56 Million EUR | 186.59% |
| 2016 Q1 | 8.92 Million EUR | -66.26% |
| 2016 Q4 | 31.01 Million EUR | 149.75% |
| 2015 Q2 | 27.33 Million EUR | 169.91% |
| 2015 Q4 | 26.43 Million EUR | 149.26% |
| 2015 FY | 26.43 Million EUR | -11.96% |
| 2015 Q1 | 10.12 Million EUR | -66.28% |
| 2015 Q3 | 10.6 Million EUR | -61.19% |
| 2014 Q3 | 12.92 Million EUR | -37.14% |
| 2014 Q4 | 30.02 Million EUR | 132.41% |
| 2014 Q2 | 20.55 Million EUR | 27.04% |
| 2014 FY | 30.02 Million EUR | 191.37% |
| 2014 Q1 | 16.17 Million EUR | 57.0% |
| 2013 Q4 | 10.3 Million EUR | 62.11% |
| 2013 FY | 10.3 Million EUR | -0.7% |
| 2013 Q3 | 6.35 Million EUR | -39.16% |
| 2013 Q2 | 10.44 Million EUR | 57.93% |
| 2013 Q1 | 6.61 Million EUR | -36.25% |
| 2012 FY | 10.37 Million EUR | -7.17% |
| 2012 Q2 | 9.68 Million EUR | 0.0% |
| 2012 Q4 | 10.37 Million EUR | 0.0% |
| 2011 Q4 | 11.17 Million EUR | 0.0% |
| 2011 FY | 11.17 Million EUR | 49.41% |
| 2011 Q2 | 10.71 Million EUR | 0.0% |
| 2010 FY | 7.48 Million EUR | -12.74% |
| 2010 Q4 | 7.48 Million EUR | 0.0% |
| 2010 Q2 | 8.15 Million EUR | 0.0% |
| 2009 Q4 | 8.57 Million EUR | 0.0% |
| 2009 FY | 8.57 Million EUR | -43.4% |
| 2008 FY | 15.14 Million EUR | -11.14% |
| 2007 FY | 17.04 Million EUR | 356.25% |
| 2006 FY | 3.73 Million EUR | 1.51% |
| 2005 FY | 3.68 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -196.123% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 84.382% |
| Adocia SA | 31.87 Million EUR | 35.777% |
| Aelis Farma SA | 13.08 Million EUR | -56.483% |
| Biophytis S.A. | 15.84 Million EUR | -29.144% |
| Advicenne S.A. | 24.37 Million EUR | 16.036% |
| genOway Société anonyme | 14.45 Million EUR | -41.554% |
| IntegraGen SA | 5.97 Million EUR | -242.286% |
| Medesis Pharma S.A. | 6.42 Million EUR | -218.509% |
| Neovacs S.A. | 3.71 Million EUR | -451.382% |
| NFL Biosciences SA | 3.62 Million EUR | -465.308% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -201.783% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -518.349% |
| Sensorion SA | 13.22 Million EUR | -54.741% |
| Theranexus Société Anonyme | 5.01 Million EUR | -308.039% |
| TME Pharma N.V. | 2.78 Million EUR | -634.937% |
| Valbiotis SA | 13.7 Million EUR | -49.314% |
| TheraVet SA | 1.48 Million EUR | -1278.323% |
| argenx SE | 402.79 Million EUR | 94.919% |
| BioSenic S.A. | 32.26 Million EUR | 36.561% |
| Celyad Oncology SA | 9.97 Million EUR | -105.131% |
| DBV Technologies S.A. | 38.74 Million USD | 47.173% |
| Galapagos NV | 1.56 Billion EUR | 98.689% |
| Genfit S.A. | 105.92 Million EUR | 80.676% |
| GeNeuro SA | 20.13 Million EUR | -1.629% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -137.668% |
| Innate Pharma S.A. | 132.29 Million EUR | 84.528% |
| Inventiva S.A. | 101.59 Million EUR | 79.853% |
| MaaT Pharma SA | 22.46 Million EUR | 8.889% |
| MedinCell S.A. | 77.77 Million EUR | 73.681% |
| Nanobiotix S.A. | 95.74 Million EUR | 78.621% |
| Onward Medical N.V. | 25.69 Million EUR | 20.352% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 18.537% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 65.355% |
| Oxurion NV | 19.73 Million EUR | -3.709% |
| Pharming Group N.V. | 228.28 Million EUR | 91.034% |
| Poxel S.A. | 53.9 Million EUR | 62.027% |
| GenSight Biologics S.A. | 34.72 Million EUR | 41.06% |
| Transgene SA | 26.51 Million EUR | 22.812% |
| Financière de Tubize SA | 123.65 Million EUR | 83.447% |
| UCB SA | 6.56 Billion EUR | 99.688% |
| Valneva SE | 341.14 Million EUR | 94.0% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -350.143% |